Deutsch English Français

Contact

EP3424931

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP3424931

EP3424931 - TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 18.12.2020 Database last updated on 24.04.2024
Former	The patent has been granted Status updated on 10.01.2020
Former	Grant of patent is intended Status updated on 06.10.2019
Former	Request for examination was made Status updated on 05.04.2019
Former	The application has been published Status updated on 07.12.2018
Most recent event Tooltip	15.07.2022	Lapse of the patent in a contracting state New state(s): MK	published on 17.08.2022 [2022/33]
Applicant(s)	For all designated states Amgen Inc. One Amgen Center Drive Thousand Oaks, California 91320-1799 / US
	[2019/44]
Former [2019/02]	For all designated states Amgen, Inc One Amgen Center Drive Thousand Oaks, CA 91320-1799 / US
Inventor(s)	01 / Brown, Sean P. 28909 Hollowbrook Avenue Agoura Hills, CA 91303 / US
	02 / LI, Yunxiao 2462 Pleasant Way Unit P Thousand Oaks, CA 91362 / US
	03 / Lizazaburu, Mike Elias 1159 Palou Drive Pacifica, CA 94044 / US
	04 / Lucas, Brian S 4 Brantwood Road Arlington, MA 02476 / US
	05 / Paras, Nick A. 1161 Sheila Lane Pacifica, CA 94044 / US
	06 / Taygerly, Joshua 213 Acadia Street San Francisco, CA 94131 / US
	07 / Vimolratana, Marc One Amgen Center Drive c/o M/S 28-5 Thousand Oaks, CA 91320 / US
	08 / Wang, Xianghong 4915 Shelton Street Dublin, CA 94568 / US
	09 / Yu, Ming 42 Williams Lane Foster City, CA 94404 / US
	10 / Zancanella, Manuel 1705 Marina Court Apt. A San Mateo, CA 94403 / US
	11 / Zhu, Liusheng 752 Orion Lane Foster City, CA 94404 / US
	12 / Gonzalez Buenrostro, Ana One Amgen Center Drive c/o M/S 28-5 Thousand Oaks, CA 91320 / US
	13 / LI, Zhihong 467 Anita Drive Millbrae, CA 94030 / US
	[2019/02]
Representative(s)	Hoffmann Eitle Patent- und Rechtsanwälte PartmbB Arabellastraße 30 81925 München / DE
	[2019/02]
Application number, filing date	18187957.8	28.08.2015
	[2019/02]
Priority number, date	US201462043929P	29.08.2014 Original published format: US 201462043929 P
	[2019/02]
Filing language	EN
Procedural language	EN
Publication	Type:	A2 Application without search report
	No.:	EP3424931
	Date:	09.01.2019
	Language:	EN
	[2019/02]
	Type:	A3 Search report
	No.:	EP3424931
	Date:	20.02.2019
	Language:	EN
	[2019/08]
	Type:	B1 Patent specification
	No.:	EP3424931
	Date:	12.02.2020
	Language:	EN
	[2020/07]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	22.01.2019
Classification	IPC:	C07D513/08, A61K31/554, A61P35/00	[2019/02]
	CPC:	C07D513/10 (EP,KR,US); C07D513/08 (EP,CN,IL,KR,US); A61K31/395 (IL); A61K31/554 (KR); A61K39/39558 (KR); A61P35/00 (EP); (+) A61P35/02 (EP); C07C311/11 (US); C07C59/56 (US); C07C59/68 (US); C07D249/18 (US); C07D498/00 (US) (-)
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2019/19]
Former [2019/02]	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Extension states	BA	28.03.2019
	ME	28.03.2019
Title	German:	VERBINDUNGEN ZUR HEMMUNG DES MCL-1-PROTEINS	[2019/02]
	English:	TETRAHYDRONAPHTHALENE DERIVATIVES THAT INHIBIT MCL-1 PROTEIN	[2019/02]
	French:	COMPOSÉS QUI INHIBENT L'EXPRESSION DE LA PROTÉINE MCL-1	[2019/02]
Examination procedure	28.03.2019	Examination requested [2019/19]
	28.03.2019	Date on which the examining division has become responsible
	27.06.2019	Amendment by applicant (claims and/or description)
	07.10.2019	Communication of intention to grant the patent
	18.12.2019	Fee for grant paid
	18.12.2019	Fee for publishing/printing paid
	18.12.2019	Receipt of the translation of the claim(s)
Parent application(s) Tooltip	EP15772048.3 / EP3186259
Opposition(s)	13.11.2020	No opposition filed within time limit [2021/03]
Fees paid	Renewal fee
	08.08.2018	Renewal fee patent year 03
	08.08.2018	Renewal fee patent year 04
	15.08.2019	Renewal fee patent year 05
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	28.08.2015
	AL	12.02.2020
	AT	12.02.2020
	CY	12.02.2020
	CZ	12.02.2020
	DK	12.02.2020
	EE	12.02.2020
	FI	12.02.2020
	HR	12.02.2020
	LT	12.02.2020
	LV	12.02.2020
	MC	12.02.2020
	MK	12.02.2020
	MT	12.02.2020
	NL	12.02.2020
	PL	12.02.2020
	RO	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	SI	12.02.2020
	SK	12.02.2020
	SM	12.02.2020
	TR	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
	PT	05.07.2020
	IE	28.08.2020
	LU	28.08.2020
	BE	31.08.2020
	[2022/31]
Former [2022/30]	HU	28.08.2015
	AL	12.02.2020
	AT	12.02.2020
	CY	12.02.2020
	CZ	12.02.2020
	DK	12.02.2020
	EE	12.02.2020
	FI	12.02.2020
	HR	12.02.2020
	LT	12.02.2020
	LV	12.02.2020
	MC	12.02.2020
	MT	12.02.2020
	NL	12.02.2020
	PL	12.02.2020
	RO	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	SI	12.02.2020
	SK	12.02.2020
	SM	12.02.2020
	TR	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
	PT	05.07.2020
	IE	28.08.2020
	LU	28.08.2020
	BE	31.08.2020
Former [2022/27]	HU	28.08.2015
	AT	12.02.2020
	CY	12.02.2020
	CZ	12.02.2020
	DK	12.02.2020
	EE	12.02.2020
	FI	12.02.2020
	HR	12.02.2020
	LT	12.02.2020
	LV	12.02.2020
	MC	12.02.2020
	MT	12.02.2020
	NL	12.02.2020
	PL	12.02.2020
	RO	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	SI	12.02.2020
	SK	12.02.2020
	SM	12.02.2020
	TR	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
	PT	05.07.2020
	IE	28.08.2020
	LU	28.08.2020
	BE	31.08.2020
Former [2021/37]	AT	12.02.2020
	CZ	12.02.2020
	DK	12.02.2020
	EE	12.02.2020
	FI	12.02.2020
	HR	12.02.2020
	LT	12.02.2020
	LV	12.02.2020
	MC	12.02.2020
	NL	12.02.2020
	PL	12.02.2020
	RO	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	SI	12.02.2020
	SK	12.02.2020
	SM	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
	PT	05.07.2020
	IE	28.08.2020
	LU	28.08.2020
	BE	31.08.2020
Former [2021/36]	AT	12.02.2020
	CZ	12.02.2020
	DK	12.02.2020
	EE	12.02.2020
	FI	12.02.2020
	HR	12.02.2020
	LT	12.02.2020
	LV	12.02.2020
	MC	12.02.2020
	NL	12.02.2020
	PL	12.02.2020
	RO	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	SI	12.02.2020
	SK	12.02.2020
	SM	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
	PT	05.07.2020
	LU	28.08.2020
	BE	31.08.2020
Former [2021/20]	AT	12.02.2020
	CZ	12.02.2020
	DK	12.02.2020
	EE	12.02.2020
	FI	12.02.2020
	HR	12.02.2020
	LT	12.02.2020
	LV	12.02.2020
	MC	12.02.2020
	NL	12.02.2020
	PL	12.02.2020
	RO	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	SI	12.02.2020
	SK	12.02.2020
	SM	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
	PT	05.07.2020
	LU	28.08.2020
Former [2021/18]	AT	12.02.2020
	CZ	12.02.2020
	DK	12.02.2020
	EE	12.02.2020
	FI	12.02.2020
	HR	12.02.2020
	LT	12.02.2020
	LV	12.02.2020
	MC	12.02.2020
	NL	12.02.2020
	PL	12.02.2020
	RO	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	SI	12.02.2020
	SK	12.02.2020
	SM	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
	PT	05.07.2020
Former [2021/11]	AT	12.02.2020
	CZ	12.02.2020
	DK	12.02.2020
	EE	12.02.2020
	FI	12.02.2020
	HR	12.02.2020
	LT	12.02.2020
	LV	12.02.2020
	NL	12.02.2020
	PL	12.02.2020
	RO	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	SI	12.02.2020
	SK	12.02.2020
	SM	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
	PT	05.07.2020
Former [2020/50]	CZ	12.02.2020
	DK	12.02.2020
	EE	12.02.2020
	FI	12.02.2020
	HR	12.02.2020
	LT	12.02.2020
	LV	12.02.2020
	NL	12.02.2020
	RO	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	SK	12.02.2020
	SM	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
	PT	05.07.2020
Former [2020/49]	CZ	12.02.2020
	DK	12.02.2020
	FI	12.02.2020
	HR	12.02.2020
	LT	12.02.2020
	LV	12.02.2020
	NL	12.02.2020
	RO	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	SK	12.02.2020
	SM	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
	PT	05.07.2020
Former [2020/48]	DK	12.02.2020
	FI	12.02.2020
	HR	12.02.2020
	LT	12.02.2020
	LV	12.02.2020
	NL	12.02.2020
	RO	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	SM	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
	PT	05.07.2020
Former [2020/47]	DK	12.02.2020
	FI	12.02.2020
	HR	12.02.2020
	LT	12.02.2020
	LV	12.02.2020
	NL	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
Former [2020/45]	FI	12.02.2020
	HR	12.02.2020
	LV	12.02.2020
	NL	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
Former [2020/40]	FI	12.02.2020
	HR	12.02.2020
	LV	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
	IS	12.06.2020
Former [2020/39]	FI	12.02.2020
	HR	12.02.2020
	LV	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	BG	12.05.2020
	NO	12.05.2020
	GR	13.05.2020
Former [2020/38]	FI	12.02.2020
	HR	12.02.2020
	LV	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	NO	12.05.2020
	GR	13.05.2020
Former [2020/37]	FI	12.02.2020
	HR	12.02.2020
	LV	12.02.2020
	RS	12.02.2020
	SE	12.02.2020
	NO	12.05.2020
Former [2020/35]	FI	12.02.2020
	NO	12.05.2020
Documents cited:	Search	[A]WO2008131000 (ABBOTT LAB [US], et al) [A] 1-13,15 * page 1, line 5 - line 7; claim 1 *;
		[A]WO2011022312 (MERCK SHARP & DOHME [US], et al) [A] 1,14* 3-4 page 35 *;
		[A]WO2013149124 (UNIV MICHIGAN [US], et al) [A] 1-13,15 * claims 1,20 *;
		[XP] - MICHAEL G. JOHNSON ET AL, "Convenient Route to Secondary Sulfinates: Application to the Stereospecific Synthesis of [alpha]- C -Chiral Sulfonamides", ORGANIC LETTERS, US, (20141121), vol. 16, no. 23, doi:10.1021/ol503208z, ISSN 1523-7060, pages 6248 - 6251, XP055513901 [XP] 1,2 * Sheme 3, 4k * DOI: http://dx.doi.org/10.1021/ol503208z
	by applicant	US4522811
		US6468798
		US6472375
		US6471996
		- BEROUKHIM et al., Nature, (20100000), vol. 463, pages 899 - 90
		- G. LESSENE; P. CZABOTAR; P. COLMAN, Nat. Rev. Drug. Discov., (20080000), vol. 7, pages 989 - 1000
		- C. AKGUL, Cell. Mol. Life Sci., (20090000), vol. 66
		- ARTHUR M. MANDELIN II; RICHARD M. POPE, Expert Opin. Ther. Targets, (20070000), vol. 11, no. 3, pages 363 - 373
		- R.C. Rowe , P.J. Sheskey, and S.C. Owen, Handbook of Pharmaceutical Excipients, 5t ed., Pharmaceutical Press, (20050000), vol. 928
		- BERGE et al., "Pharmaceutical Salts", J. Pharm. Sci., (19770000), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560 DOI: http://dx.doi.org/10.1002/jps.2600660104
		- HAMAJIMA et al., Clin. Immunol. Immunopathol., (19980000), vol. 88, no. 2, pages 205 - 10
		- S. M. BERGE et al., "Pharmaceutical Salts", J Pharm Sci, (19770000), vol. 66, doi:doi:10.1002/jps.2600660104, pages 1 - 19, XP002675560 DOI: http://dx.doi.org/10.1002/jps.2600660104
		- T. HIGUCHI; W. STELLA, "Pro-drugs as Novel Delivery Systems", T. HIGUCHI; W. STELLA, Edward B. Roche, A.C.S. Symposium Series, and in Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, (19870000), vol. 14
		- BRUBAKER, J.D.; MYERS, A.G., Org. Lett., (20070000), vol. 9, pages 3523 - 3525
		- KRASOVSKIY, A.; KNOCHEL, P., Synthesis, (20060000), pages 890 - 891
		- SIGMAN, M. S. et al., J. Am. Chem. Soc., (19990000), vol. 134, no. 28, pages 11408 - 11411
		- SIGMAN, M. S. et al., J. Am. Chem. Soc., (20120000), vol. 134, no. 28, pages 11408 - 11411

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 35p